Literature DB >> 17473939

Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.

Marco Scarpa1, Renata D'Incà, Daniela Basso, Cesare Ruffolo, Lino Polese, Eugenia Bertin, Alessia Luise, Mauro Frego, Mario Plebani, Giacomo C Sturniolo, Davide F D'Amico, Imerio Angriman.   

Abstract

PURPOSE: This study was designed to assess the role of fecal lactoferrin and calprotectin as markers of intestinal inflammation in patients with Crohn's disease who have undergone ileocolonic resection.
METHODS: Sixty-three patients who had undergone ileocolonic resection for Crohn's disease with a median follow-up of 40.5 (range, 5-102) months were enrolled. Clinical examination and blood test were performed, and fecal lactoferrin and calprotectin levels were dosed. The predictors for fecal lactoferrin and calprotectin levels that resulted to be significant at the univariate analyses were included in two multiple regression analysis models.
RESULTS: The mean lactoferrin level was 21 +/- 3.9 microg/g and the mean calprotectin fecal level was 247 +/- 22.7 ng/ml. C-reactive protein levels (P < 0.01), calprotectin levels (P < 0.01), and the presence of clinical recurrence (P = 0.04) resulted to be independent predictors of lactoferrin levels. Only lactoferrin levels resulted to be an independent predictor for calprotectin fecal levels (P < 0.01).
CONCLUSIONS: Crohn's disease patients maintain high fecal levels of lactoferrin and calprotectin at long-term follow-up after resection of the diseased bowel even in case of clinical remission. The significant correlation between the two fecal markers may be the expression of the ongoing intestinal inflammation. Only lactoferrin significantly correlated with C-reactive protein and showed a reliable threshold value for systemic inflammation. Lactoferrin fecal levels may be a reliable indicator for intestinal inflammation influencing the systemic inflammatory status. The third predictor of lactoferrin fecal level was the presence of episodes of clinical recurrence during the postoperative follow-up.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473939     DOI: 10.1007/s10350-007-0225-6

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  31 in total

Review 1.  Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis.

Authors:  Yan Wang; Fengyan Pei; Xingjuan Wang; Zhiyu Sun; Chengjin Hu; Hengli Dou
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 2.  Enteric infections, diarrhea, and their impact on function and development.

Authors:  William A Petri; Mark Miller; Henry J Binder; Myron M Levine; Rebecca Dillingham; Richard L Guerrant
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

3.  Clinical significance of inflammatory markers.

Authors:  Bincy P Abraham; Selvi Thirumurthi
Journal:  Curr Gastroenterol Rep       Date:  2009-10

Review 4.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

Review 5.  Biomarkers in inflammatory bowel disease: current practices and recent advances.

Authors:  Heba N Iskandar; Matthew A Ciorba
Journal:  Transl Res       Date:  2012-02-01       Impact factor: 7.012

6.  Innate immune environment in ileal pouch mucosa: α5 defensin up-regulation as predictor of chronic/relapsing pouchitis.

Authors:  Marco Scarpa; Alessia Grillo; Melania Scarpa; Paola Brun; Carlo Castoro; Anna Pozza; Donatella Cavallo; Diego Faggian; Cesare Ruffolo; Renata D'Incà; Romeo Bardini; Ignazio Castagliuolo; Imerio Angriman
Journal:  J Gastrointest Surg       Date:  2011-10-08       Impact factor: 3.452

Review 7.  Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease.

Authors:  Anastassios C Manolakis; Andreas N Kapsoritakis; Elisavet K Tiaka; Spyros P Potamianos
Journal:  Dig Dis Sci       Date:  2011-01-04       Impact factor: 3.199

8.  Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease.

Authors:  Gilles Boschetti; Marc'harid Laidet; Driffa Moussata; Carmen Stefanescu; Xavier Roblin; Gildas Phelip; Eddy Cotte; Guillaume Passot; Yves Francois; Jocelyne Drai; Emilie Del Tedesco; Yoram Bouhnik; Bernard Flourie; Stephane Nancey
Journal:  Am J Gastroenterol       Date:  2015-03-17       Impact factor: 10.864

Review 9.  Diagnostic advances in inflammatory bowel disease (imaging and laboratory).

Authors:  Maria E Moscandrew; Edward V Loftus
Journal:  Curr Gastroenterol Rep       Date:  2009-12

10.  Subclinical intestinal inflammation in patients with Crohn's disease following bowel resection: a smoldering fire.

Authors:  Cesare Ruffolo; Marco Scarpa; Diego Faggian; Daniela Basso; Renata D'Incà; Mario Plebani; Giacomo C Sturniolo; Nicolò Bassi; Imerio Angriman
Journal:  J Gastrointest Surg       Date:  2009-11-10       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.